NCT00535873View on ClinicalTrials.gov

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

PHASE2CompletedINTERVENTIONAL

Enrollment

61

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

LeukemiaCLLChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Interventions

DRUG

Lenalidomide

Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Celgene

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER